MASHINIi

Jade Biosciences, Inc..

JBIO.US | Research and experimental development on natural sciences and engineering

Jade Biosciences, Inc. is a biotechnology company focused on the discovery, development, and commercialization of novel therapeutics for unmet medical needs. The company's pipeline includes product candidates targeting various diseases. Jade Biosciences utilizes its proprietary technology platforms ...Show More

Ethical Profile

Mixed.

Jade Biosciences, Inc. (JBIO.US) is primarily focused on developing therapies for autoimmune diseases, aligning with a 'Better Health for All' mission. The company has invested $20.0 million in R&D in Q1 2025, including $10.0 million specifically for its JADE101 therapy, with a first-in-human clinical trial planned for late 2025. While its core mission shows significant commitment, comprehensive data on other ethical areas is limited. Reports suggest that as a biotech, it likely engages in animal testing during preclinical development. Information regarding fair pay, ethical sourcing, environmental impact, or community engagement is currently insufficient for a full assessment.

Value Scores

Better Health for All40
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals-40
-100100
No War, No Weapons0
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

40

Jade Biosciences is a biotechnology company focused on the discovery and development of novel therapies for unmet medical needs, specifically autoimmune diseases.

1
Its entire business is devoted to health improvement, with a pipeline of potentially best-in-class therapies aimed at transforming the standard of care for patients.
2
The company has no products with established negative health outcomes.
3
In Q1 2025, the company reported $20.0 million in R&D expenses, with $10.0 million specifically allocated to JADE101 development.
4
The company plans to initiate a first-in-human clinical trial for JADE101 in the second half of 2025, with interim data expected in the first half of 2026.
5
The company has stated its commitment to conducting clinical trials with integrity and transparency, adhering to ethical guidelines and regulatory requirements.

Fair Money & Economic Opportunity

0

No evidence available to assess Jade Biosciences, Inc. on Fair Money & Economic Opportunity.

Fair Pay & Worker Respect

0

No evidence available to assess Jade Biosciences, Inc. on Fair Pay & Worker Respect.

Fair Trade & Ethical Sourcing

0

No evidence was found in the provided articles regarding Jade Biosciences, Inc.'s fair trade certifications, audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in supplier contracts, materials risk index, or supplier diversity spend.

1
The articles explicitly state a lack of information on ethical sourcing or supply chain practices, focusing instead on company financing, governance, and product pipeline.
2

Honest & Fair Business

0

No specific, concrete evidence was found in the provided articles for any of the KPIs related to Honest & Fair Business, such as regulatory fines, transparency index scores, company-wide whistleblower policies, financial restatements, audit coverage, ESG controversy scores, complaint resolution times, board conflict of interest percentages, anti-corruption policies, or third-party verification of ethical claims. A clause in the CEO's employment agreement acknowledges whistleblower rights for that individual.

1
but this does not constitute a formal company-wide whistleblower protection policy.

Kind to Animals

-40

Jade Biosciences conducts pre-clinical studies of its drugs on animals to assess product safety.

1
The article provides no further details on the company's animal testing policy, such as commitments to reduction, specific restrictions, or oversight mechanisms, suggesting a policy that permits routine animal testing without transparent limitations.

No War, No Weapons

0

The provided articles for Jade Biosciences (JBIO.US) focus exclusively on the company's pipeline for autoimmune diseases and participation in investor conferences.

1
No information or quantitative data is available regarding the company's involvement in the arms industry, defense contracts, dual-use technology, peacebuilding initiatives, or any other metrics relevant to the 'No War, No Weapons' ethical value.
2
Therefore, no KPIs can be scored based on the evidence provided.

Planet-Friendly Business

0

No specific, quantitative data for Jade Biosciences, Inc. (JBIO.US) was found across the provided articles for any of the Planet-Friendly Business KPIs.

1
Articles explicitly state that sustainability data is unavailable or that no data relevant to the requested metrics is provided for JBIO.US.
2
The other articles discuss general industry trends and averages for the biotechnology and pharmaceutical sectors, but do not provide company-specific metrics, targets, or performance data for JBIO.US.
3

Respect for Cultures & Communities

0

No specific, concrete data points related to 'Respect for Cultures & Communities' were found in the provided articles for Jade Biosciences, Inc.

1
The articles primarily focus on company funding, leadership, and product pipeline, without addressing community engagement, cultural impact, or related metrics.
2

Safe & Smart Tech

0

No evidence available to assess Jade Biosciences, Inc. on Safe & Smart Tech.

Zero Waste & Sustainable Products

0

No specific, concrete data points or facts regarding JBIO.US's performance on any of the 'Zero Waste & Sustainable Products' KPIs were found in the provided articles.

1
The articles discuss general industry initiatives in green chemistry and laboratory sustainability but do not contain company-specific information for Jade Biosciences, Inc.
2

Own Jade Biosciences, Inc.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.